Crit Rev Immunol

Immunotherapy of colon cancer using chimeric mAb 31.1.

Arlen M. Tsang A. Wang T.
Dept. of Immunology, Medical University of South Carolina, USA.
We have produced two monoclonal antibodies specific for membranes of colon carcinoma cells that demonstrate minimal if any cross reactivity with normal colon tissue. The antigen of one of the two antibodies (mAb 33.28) is extremely immunogenic eliciting both cell mediated and humoral immunity. The monoclonal antibodies developed in in vitro studies suggested strong antibody dependent cell cytotoxicity (ADCC) for both antibodies, but somewhat stronger for the mAb 31.1. The murine version of mAb 31.1 produced approximately 90% tumor cell destruction in the same period of time. Nude mice with LS174T xenografts (human colon carcinoma) were challenged with 1 x 10(6) cells given subcutaneously in the thigh. By day 10, well animals were incapacitated by tumor growth. Among those animals receiving 400 micrograms of intraperitoneal chimeric 31.1 at day one, all were protected and remained free of disease. Those challenged with chimeric antibody and human effector cells at day 7 demonstrated regression of established tumor nodules among 80% of the animals so treated. Therapy of patients with extensive primary as well as metastatic colon cancer may be found to respond to the above form of therapy post surgery, when employed alone or in combination with an effective cytotoxic (chemotherapeutic) agent.